Effectiveness of the Diabetes Homeless Medication Support (D-HOMES) Program on Diabetes Management
Part of paid clinical trials in Minneapolis, Minnesota.
- Sponsor
- Katherine Vickery
- Study ID
- NCT07091487
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Diabetes Homeless Medication Support — BEHAVIORALThere will be 10 one-on-one sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors and psychologiccal wellness to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool matched to the patient's needs/goals and tailored diabetes education as needed.
- Enhanced Usual Care/ Education — BEHAVIORALTrained diabetes wellness coaches will provide approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will use the ask-offer-ask method to review these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
Study Details
The goal of this clinical trial is to learn if the Diabetes Homelessness Medication Support (D-HOMES) wellness coaching model is effective for adults who speak English or Spanish, have Type 2 diabetes with an HbA1c at or above 7.5, and have recently experienced homelessness. Researchers will compare a one-time education session about diabetes to 10 wellness coaching sessions to see if there are differences between the groups' health outcomes. The main questions it aims to answer are: * Do D-HOMES participants have greater reductions in HbA1c at 3 months than participants who received education? * Do D-HOMES participants have greater reductions in HbA1c at 6 and 12 months compared to those who received education? * Do D-HOMES participants have improvements in blood pressure control, quality of life, self-reported psychological wellness, diabetes distress, and diabetes medication adherence and self-management at 3, 6, and 12 months? * What factors must be considered to make D-HOMES scalable? Participants will: * complete 5 assessments including two baseline assessments and follow-ups at months 3,6, and 12 * participate in a one-time education session or 10 weeks of wellness coaching.
Key Dates
- Start date
- Jun 25, 2025
- Status verified
- Jul 2025
- Primary completion
- Dec 30, 2028
- Completion
- Sep 30, 2029
Study Design
- Enrollment
- 256 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Enhanced Usual Care/Education SessionBrief one-on-one diabetes education session provided by a diabetes wellness coach.
- Experimental: Diabetes Homeless Medication Support (D-HOMES)10 one-on-one behavioral treatments by a diabetes wellness coach.
Primary Outcome Measure
Change in HbA1c at 3 months [ Time Frame: From Baseline 1 to Month 3 assessment ]
Central Contacts
- Katherine D Vickery, MD, MSc6128736852
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Hennepin Healthcare Research Institute | Minneapolis | Minnesota | 55404 | Katherine D Vickery, MD, MSc (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Minneapolis, MN
Related Studies
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II DiabetesRecruiting · Endogenex, Inc. · Birmingham, Alabama
- Personalized Nutrition for Type 2 DiabetesRecruiting · University of Minnesota · Minneapolis, Minnesota
- The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 DiabetesPHASE2 · Recruiting · Mayo Clinic · Rochester, Minnesota
- Clinical Decision Support With Continuous Glucose Monitoring Data for Managing Type 2 DiabetesEnrolling By Invitation · HealthPartners Institute · Minneapolis, Minnesota